Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

Kimmie Ng*, Jeffrey A. Meyerhardt, Andrew T. Chan, Kaori Sato, Jennifer A. Chan, Donna Niedzwiecki, Leonard B. Saltz, Robert J. Mayer, Al B Benson III, Paul L. Schaefer, Renaud Whittom, Alexander Hantel, Richard M. Goldberg, Alan P. Venook, Shuji Ogino, Edward L. Giovannucci, Charles S. Fuchs

*Corresponding author for this work

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95% CI = 0.36 to 1.04) and 0.48 (95% CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95% CI = 0.27 to 1.04), 0.60 (95% CI = 0.33 to 1.08), and 0.50 (95% CI = 0.23 to 1.07), and HRs of 0.47 (95% CI = 0.24 to 0.91) and 0.26 (95% CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.

Original languageEnglish (US)
JournalJournal of the National Cancer Institute
Volume107
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Cyclooxygenase 2 Inhibitors
Colonic Neoplasms
Aspirin
Confidence Intervals
Disease-Free Survival
Survival
Recurrence
Adjuvant Chemotherapy
Observational Studies
Prospective Studies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ng, K., Meyerhardt, J. A., Chan, A. T., Sato, K., Chan, J. A., Niedzwiecki, D., ... Fuchs, C. S. (2015). Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. Journal of the National Cancer Institute, 107(1). https://doi.org/10.1093/jnci/dju345
Ng, Kimmie ; Meyerhardt, Jeffrey A. ; Chan, Andrew T. ; Sato, Kaori ; Chan, Jennifer A. ; Niedzwiecki, Donna ; Saltz, Leonard B. ; Mayer, Robert J. ; Benson III, Al B ; Schaefer, Paul L. ; Whittom, Renaud ; Hantel, Alexander ; Goldberg, Richard M. ; Venook, Alan P. ; Ogino, Shuji ; Giovannucci, Edward L. ; Fuchs, Charles S. / Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. In: Journal of the National Cancer Institute. 2015 ; Vol. 107, No. 1.
@article{efa5427f676b49c08041df4b2a57d5bf,
title = "Aspirin and COX-2 inhibitor use in patients with stage III colon cancer",
abstract = "We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95{\%} confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95{\%} CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95{\%} CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95{\%} CI = 0.36 to 1.04) and 0.48 (95{\%} CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95{\%} CI = 0.27 to 1.04), 0.60 (95{\%} CI = 0.33 to 1.08), and 0.50 (95{\%} CI = 0.23 to 1.07), and HRs of 0.47 (95{\%} CI = 0.24 to 0.91) and 0.26 (95{\%} CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.",
author = "Kimmie Ng and Meyerhardt, {Jeffrey A.} and Chan, {Andrew T.} and Kaori Sato and Chan, {Jennifer A.} and Donna Niedzwiecki and Saltz, {Leonard B.} and Mayer, {Robert J.} and {Benson III}, {Al B} and Schaefer, {Paul L.} and Renaud Whittom and Alexander Hantel and Goldberg, {Richard M.} and Venook, {Alan P.} and Shuji Ogino and Giovannucci, {Edward L.} and Fuchs, {Charles S.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1093/jnci/dju345",
language = "English (US)",
volume = "107",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

Ng, K, Meyerhardt, JA, Chan, AT, Sato, K, Chan, JA, Niedzwiecki, D, Saltz, LB, Mayer, RJ, Benson III, AB, Schaefer, PL, Whittom, R, Hantel, A, Goldberg, RM, Venook, AP, Ogino, S, Giovannucci, EL & Fuchs, CS 2015, 'Aspirin and COX-2 inhibitor use in patients with stage III colon cancer', Journal of the National Cancer Institute, vol. 107, no. 1. https://doi.org/10.1093/jnci/dju345

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. / Ng, Kimmie; Meyerhardt, Jeffrey A.; Chan, Andrew T.; Sato, Kaori; Chan, Jennifer A.; Niedzwiecki, Donna; Saltz, Leonard B.; Mayer, Robert J.; Benson III, Al B; Schaefer, Paul L.; Whittom, Renaud; Hantel, Alexander; Goldberg, Richard M.; Venook, Alan P.; Ogino, Shuji; Giovannucci, Edward L.; Fuchs, Charles S.

In: Journal of the National Cancer Institute, Vol. 107, No. 1, 01.01.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

AU - Ng, Kimmie

AU - Meyerhardt, Jeffrey A.

AU - Chan, Andrew T.

AU - Sato, Kaori

AU - Chan, Jennifer A.

AU - Niedzwiecki, Donna

AU - Saltz, Leonard B.

AU - Mayer, Robert J.

AU - Benson III, Al B

AU - Schaefer, Paul L.

AU - Whittom, Renaud

AU - Hantel, Alexander

AU - Goldberg, Richard M.

AU - Venook, Alan P.

AU - Ogino, Shuji

AU - Giovannucci, Edward L.

AU - Fuchs, Charles S.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95% CI = 0.36 to 1.04) and 0.48 (95% CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95% CI = 0.27 to 1.04), 0.60 (95% CI = 0.33 to 1.08), and 0.50 (95% CI = 0.23 to 1.07), and HRs of 0.47 (95% CI = 0.24 to 0.91) and 0.26 (95% CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.

AB - We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95% CI = 0.36 to 1.04) and 0.48 (95% CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95% CI = 0.27 to 1.04), 0.60 (95% CI = 0.33 to 1.08), and 0.50 (95% CI = 0.23 to 1.07), and HRs of 0.47 (95% CI = 0.24 to 0.91) and 0.26 (95% CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84926518325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926518325&partnerID=8YFLogxK

U2 - 10.1093/jnci/dju345

DO - 10.1093/jnci/dju345

M3 - Article

C2 - 25432409

AN - SCOPUS:84926518325

VL - 107

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -